Mutant huntingtin represses CBP, but not p300, by binding and protein degradation

被引:35
作者
Cong, SY
Pepers, BA
Evert, BO
Rubinsztein, DC
Roos, RAC
van Ommen, GJB
Dorsman, JC
机构
[1] Leiden Univ, Ctr Med, CBG Ctr Human & Clin Genet, NL-2333 AL Leiden, Netherlands
[2] Leiden Univ, Ctr Med, Dept Neurol, Leiden, Netherlands
[3] China Med Univ, Affiliated Hosp 2, Dept Neurol, Shenyang, Peoples R China
[4] Univ Bonn, Dept Neurol, D-5300 Bonn, Germany
[5] Cambridge Inst Med Res, Dept Med Genet, Cambridge, England
[6] Ctr Med Syst Biol, Leiden, Netherlands
[7] Ctr Med Syst Biol, Amsterdam, Netherlands
[8] Ctr Med Syst Biol, Rotterdam, Netherlands
[9] Vrije Univ Amsterdam, Ctr Med, NL-1081 HV Amsterdam, Netherlands
关键词
D O I
10.1016/j.mcn.2005.05.003
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huntington's disease can be used as a model to study neurodegenerative disorders caused by aggregation-prone proteins. It has been proposed that the entrapment of transcription factors in aggregates plays an important role in pathogenesis. We now report that the transcriptional activity of CBP is already repressed in the early time points by soluble mutant huntingtin, whereas the histone acetylase activity of CBP/p300 is gradually diminished over time. Mutant huntingtin bound much stronger to CBP than normal huntingtin, possibly contributing to repression. Especially at the later time points, CBP protein level was gradually reduced via the proteasome pathway. In sharp contrast, p300 was unaffected by mutant huntingtin. This selective degradation of CBP was absent in spinocerebellar ataxia 3. Thus, mutant huntingtin specifically affects CBP and not p300 both at the early and later time points, via multiple mechanisms. In addition to the reduction of CBP, also the altered ratio of these closely related histone acetyltransferases may affect chromatin structure and transcription and thus contribute to neurodegeneration. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:12 / 23
页数:12
相关论文
共 50 条
[31]   Update - CBP/p300 transgenic mice [J].
Giles, RH .
TRENDS IN GENETICS, 1998, 14 (06) :214-214
[32]   Role of Intrinsic Protein Disorder in the Function and Interactions of the Transcriptional Coactivators CREB-binding Protein (CBP) and p300 [J].
Dyson, H. Jane ;
Wright, Peter E. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2016, 291 (13) :6714-6722
[33]   Plant orthologs of p300/CBP:: conservation of a core domain in metazoan p300/CBP acetyltransferase-related proteins [J].
Bordoli, L ;
Netsch, M ;
Lüthi, U ;
Lutz, W ;
Eckner, R .
NUCLEIC ACIDS RESEARCH, 2001, 29 (03) :589-597
[34]   Regulation of the homeodomain CCAAT displacement/cut protein function by histone acetyltransferases p300/CREB-binding protein (CBP)-associated factor and CBP [J].
Li, SD ;
Aufiero, B ;
Schiltz, RL ;
Walsh, MJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (13) :7166-7171
[35]   Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53 [J].
Zhu, QZ ;
Yao, JH ;
Wani, G ;
Wani, MA ;
Wani, AA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (32) :29695-29701
[36]   P300 IS A FUNCTIONAL HOMOLOG OF THE TRANSCRIPTIONAL COACTIVATOR CBP [J].
LUNDBLAD, JR ;
KWOK, RPS ;
LAURANCE, ME ;
HARTER, ML ;
GOODMAN, RH .
FASEB JOURNAL, 1995, 9 (06) :A1461-A1461
[37]   Chromatin recognition and regulation of the acetyltransferase CBP/p300 [J].
Panne, D. .
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2014, 70 :C1586-C1586
[38]   Role of CBP/P300 in nuclear receptor signalling [J].
Chakravarti, D ;
LaMorte, VJ ;
Nelson, MC ;
Nakajima, T ;
Schulman, IG ;
Juguilon, H ;
Montminy, M ;
Evans, RM .
NATURE, 1996, 383 (6595) :99-103
[39]   Molecular cloning and expression of Xenopus p300/CBP [J].
Fujii, G ;
Tsuchiya, R ;
Itoh, Y ;
Tashiro, K ;
Hirohashi, S .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 1998, 1443 (1-2) :41-54
[40]   Binding of p300/CBP co-activators by polyoma large T antigen [J].
Cho, SY ;
Tian, Y ;
Benjamin, TL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (36) :33533-33539